Observe ZDNET: Add us as a preferred source on Google.
ZDNET’s key takeaways
- Life sciences leaders say AI brokers will likely be “important” inside two years.
- 97% say trusted knowledge is crucial for efficient use of AI brokers.
- 81% of R&D leaders surveyed are “very excited” about utilizing AI.
Life sciences leaders are more and more adopting AI and AI agents to deal with rising business disruption. This shift is happening because the sector confronts new regulatory demands that strain compliance teams, more and more advanced scientific trials, and rising expectations from healthcare professionals.
A latest Salesforce examine revealed that life sciences leaders see AI as a robust device for navigating these challenges, with 94% anticipating AI brokers to be vital for scaling organizational capability and strengthening operations.
Additionally: AI is every developer’s new reality – 5 ways to make the most of it
The analysis additionally recognized three key areas the place AI will help stabilize the business: compliance, scientific trials, and healthcare skilled (HCP) engagement. Notably, 96% of the leaders surveyed imagine that AI brokers will likely be “important” inside the subsequent two years.
Knowledge is the largest problem
Whereas there’s important enthusiasm, with 72% of leaders expressing pleasure about AI, a number of key limitations are hindering its full implementation and growth. The highest challenges embody:
- Safety, privateness, and compliance considerations.
- Organizational change administration.
- Uncertainty relating to regulatory steerage on AI use.
- Issues about unproven or unfamiliar AI platforms.
- Problem integrating AI into current instruments and workflows.
A vital think about constructing belief amongst life sciences professionals is the reliability of the underlying platform and knowledge. Practically all leaders (97%) agree that trusted data is essential for effective AI agent use, and 96% imagine a broadly used or confirmed platform is necessary for confidence in utilizing AI at work.
Additionally: 50 AI agents get their first annual performance review – 6 lessons learned
The Salesforce survey revealed that solely 46% of life sciences technical leaders are absolutely assured within the constant availability, timeliness, and accuracy of their knowledge.
AI in healthcare engagement
Regardless of billions of {dollars} spent on HCP engagement, over a 3rd of leaders believed their methods are ineffective. A significant contributing issue is the overload of generic messages that HCPs obtain, resulting in disengagement.
In 2024 alone, US healthcare and pharmaceutical firms spent over $30bn on promoting. Multiple in three (37%) life sciences leaders mentioned their HCP engagement methods (together with gross sales and advertising) are damaged, and 31% mentioned their gross sales and advertising groups should not scaling successfully with product launches.
Additionally: AI just passed a brutal finance exam most humans fail – should analysts be worried?
Weak segmentation methods look like a big trigger. Business leaders estimated that 30% of their gross sales and advertising efforts are wasted, break up between concentrating on the improper folks and sending the improper message. Whereas 58% take into account their segmentation technique superior, solely 4% view their outreach as “cutting-edge.”
This confidence could possibly be an overestimation, as solely 62% take into account affected person inhabitants demographics, and a mere 39% think about digital behaviors, reminiscent of channel preferences or content material consumption patterns.
Life science leaders believed AI brokers can summarize, streamline, and reply to HCP communications. A hanging 63% of economic leaders mentioned they’re “very excited” about integrating AI into their each day work. Beneficial AI use instances for HCP engagement embody:
- Summarizing communications between firms and HCPs (89%).
- Streamlining HCP interactions throughout channels (88%).
- Responding to HCP medical inquiries 24/7 (87%).
- Bettering promoting and gross sales engagement (78%).
These outcomes spotlight a transparent alternative for AI to deal with vital inefficiencies and improve the effectiveness of HCP engagement.
AI in scientific trials
Life sciences leaders are dealing with important challenges, with scientific trials remaining the most costly and sometimes delayed step in remedy growth. Market swings, coverage adjustments, and provide chain disruptions compound current points, reminiscent of guide workflows and difficulties in monitoring long-term outcomes.
Additionally: AI helps strong dev teams and hurts weak ones, according to Google’s 2025 DORA report
Over half (57%) of life science leaders acknowledged main disruptions in trials as a consequence of these exterior elements. The highest limitations to assembly new trial necessities embody:
- Handbook regulatory workflows (55%).
- Problem monitoring long-term outcomes (38%).
- Disconnected R&D and scientific operations (25%).
- Website onboarding delays (25%).
- Recruitment and retention struggles (24%).
In response, 94% of leaders acknowledged that evolving trial necessities are reshaping their strategy to innovation, with AI rising as a vital resolution. R&D leaders, particularly, are keen about AI, with 81% expressing pleasure about its software of their each day work.
General, over 90% of life sciences leaders considered AI in scientific trials as a helpful resolution. Among the prime AI use instances thought of embody:
- Scientific trial web site choice (94%).
- Offering real-time affected person final result insights (92%).
- Matching candidates to scientific trials (92%).
- Scientific trial participant recruitment and engagement (91%).
These insights emphasize the necessity for superior options to streamline scientific trials and speed up remedy growth.
Compliance is a vital AI use case
Increasing laws and intensifying audits are considerably impacting compliance groups, with 64% of life sciences leaders reporting their workloads are “closely impacted” by latest volatility.
Curiously, compliance is each the highest issue dampening AI enthusiasm in life sciences and the main focus of its three most respected use instances. Elements that curb pleasure embody compliance dangers, an absence of change administration plans, and an absence of belief in underlying knowledge. Conversely, probably the most helpful AI use instances recognized are: first, document generation, consent, and contract management; second, regulatory reporting; and third, streamlining compliance.
Additionally: Got AI FOMO? 3 bold but realistic bets your business can try today
Finally, AI is considered as a tool to reduce routine task workloads, increase compliance requirements, and assist groups preserve tempo with evolving laws. A major 94% of life sciences leaders believed AI brokers could be vital in managing these altering laws.
To study extra about how healthcare and life sciences professionals are leveraging AI, you’ll be able to go to here.
